2-Acetoxy-naphthalin-6-sulfonsaeurechlorid | 37845-39-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Acetoxy-naphthalin-6-sulfonsaeurechlorid
• 英文别名: 6-acetoxy-naphthalene-2-sulfonyl chloride；6-Acetoxy-naphthalin-2-sulfonylchlorid；2-Acetoxy-naphthalin-sulfonsaeure-(6)-chlorid；6-acetoxynaphthyl-2-sulfonyl chloride；(6-chlorosulfonylnaphthalen-2-yl) acetate
• CAS: 37845-39-9
• 化学式: C₁₂H₉ClO₄S
• 分子量: 284.72
• InChiKey: QLKAEIJFEMKGNO-UHFFFAOYSA-N

物化性质

• 熔点：
  103 °C
• 沸点：
  441.7±20.0 °C(Predicted)
• 密度：
  1.439±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Acetoxy-naphthalin-6-sulfonsaeurechlorid 在 水 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13

  摘要：

  The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would provide a disease modifying therapy for the treatment of arthritis, although this goal still continues to elude the pharmaceutical industry due to issues with safety. Our efforts have resulted in the discovery of a series of hydroxamic acid inhibitors of MMP-13 that do not significantly inhibit MMP-2 (gelatinase-1). MMP-2 has been implicated in the musculoskeletal side effects resulting from pan-MMP inhibition due to findings from spontaneously occurring human MMP-2 deletions. Analysis of the SAR of hundreds of previously prepared hydroxamate based MMP inhibitors lead us to 2-naphthylsulfonamide substituted hydroxamates which exhibited modest selectivity for MMP-13 versus MMP-2. This Letter describes the lead optimization of 1 and identification of inhibitors exhibiting >100-fold selectivity for MMP-13 over MMP-2 (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.087
• 作为产物：
  描述：

  sodium 2-naphthol-6-sulfonate 在 氯化亚砜 、 硫酸 、 N,N-二甲基甲酰胺 作用下， 反应 12.0h， 生成 2-Acetoxy-naphthalin-6-sulfonsaeurechlorid
  参考文献：
  名称：

  흑색 아조-금속 착물, 이를 포함하는 감광성 수지 조성물 및 이를 이용하여 제조된 경화막

  摘要：

  本发明涉及黑色偶氮-金属络合物，包括含有该物质的感光树脂组合物，以及由此制造的彩色滤光片，本发明的黑色偶氮-金属络合物具有优良的热稳定性、耐化学性和溶解性，含有该物质的感光树脂组合物和制造的彩色滤光片具有优异的色彩保持率、光学密度和表面抗性等光学特性。

  公开号：

  KR20180058545A

文献信息

• Guanidine derivatives compositions and use
  申请人：Hofmann-La Roche Inc.

  公开号：US05260307A1

  公开（公告）日：1993-11-09

  Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.

  式中L、M、R、T和X在描述中阐述的化合物I，以及其水合物或溶剂化物，可以抑制血浆中凝血酶诱导的血小板聚集和纤维蛋白原的凝结。化合物I可以通过酰胺化或酯化反应来制备，具体取决于L是NH还是O。
• [EN] SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP-12 ET MMP-13 À BASE D'ACIDE HYDROXAMIQUE
  申请人：NOVARTIS AG

  公开号：WO2010007027A1

  公开（公告）日：2010-01-21

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种具有化学式(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-12和/或MMP-13异常活性特征的疾病或疾病。因此，化合物的化学式(I)可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括化学式(I)的化合物的药物组合物。
• SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
  申请人：McQuire Leslie Wighton

  公开号：US20110112076A1

  公开（公告）日：2011-05-12

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种式子为(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式(I)的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式(I)的化合物的药物组合物。
• Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors
  申请人：McQuire Leslie Wighton

  公开号：US08841291B2

  公开（公告）日：2014-09-23

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一个式（I）的化合物：所述化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式（I）的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式（I）的化合物的药物组合物。
• Heller, Journal fur praktische Chemie (Leipzig 1954), 1929, vol. <2> 121, p. 201
  作者：Heller

  DOI：——

  日期：——